Last reviewed · How we verify

NCT05948124

Carnitine Supplementation in Pediatric Hemodialysis Patients

Status unknown EARLY_PHASE1 Last updated 17 July 2023
What this trial tests

EARLY_PHASE1 trial testing L-carnitine in Carnitine Deficiency Due to Hemodialysis in 40 participants. Status unknown.

Timeline
1 August 2023
Primary endpoint
1 February 2024
1 March 2024

Quick facts

Lead sponsorAin Shams University
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment40
Start date1 August 2023
Primary completion1 February 2024
Estimated completion1 March 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Under 16, any sex, with Carnitine Deficiency Due to Hemodialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is: 1. To determine the prevalence of carnitine deficiency among pediatric patients on hemodialysis. 2. To evaluate the efficiency of carnitine supplementation in children on regular hemodialysis with carnitine deficiency in the treatment of renal anemia, cardiac dysfunction, dyslipidemia, intradialytic muscle cramps and hypotension and their quality of life.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of L-carnitine

Trials testing the same drug.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05948124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing